Literature DB >> 350900

Modification by suppressor cells and serum factors of the cell-mediated immune response in experimental pyelonephritis.

T Miller, L Scott, E Stewart, D North.   

Abstract

A marked suppression of the thymusderived (T)-lymphocyte response to concanavalin A has been demonstrated in vitro during renal infection. Suppression of the T-lymphocyte response in vitro was seen as early as 2 h after the induction of renal infection, but maximum suppression was found 24-72 h later. A population of suppressor cells in the splenic lymphocyte population, generated during the host's response to infection, contributed to the depressed lymphocyte response. Removal of suppressor cells restored the mitogenic responsiveness of the remaining splenic lymphocytes. Conversely, in co-culture experiments, a suppressor cell present in the splenic lymphocyte population of pyelonephritic animals was shown to be capable of suppressing the mitogenic responsiveness of normal splenic lymphocytes. Significantly reduced host vs. graft responses by the pyelonephritic animals confirmed, in vivo, the depression of cell-mediated immune mechanisms. An additional suppressive factor was found in the serum of pyelonephritic animals which depressed in vitro the mitogenic responsiveness of splenic lymphocytes from normal animals. Support for the suppressive role of this serum factor was found when splenic lymphocytes from pyelonephritic animals were tested in vivo in the absence of homolgous serum (graft vs. host). Under these conditions, the lymphocytes showed an enhanced reaction compared with lymphocytes from normal animals. The presence of a suppressor cell population and a serum factor, both capable of depressing cell-mediated mechanisms, may be major factors contributing to the establishment of infection in the kidney.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 350900      PMCID: PMC372614          DOI: 10.1172/JCI109021

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Cellular immunity in pyelonephritis: identification of suppressor cell activity of spleen cells in response to concanavalin A and inhibition of lymphocyte-mediated L cell cytotoxicity.

Authors:  T W Williams; A M Friedlander; J M Lyons; A I Braude
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

2.  Regulation of the immune response. I. Suppression of delayed-type hypersensitivity by T cells from mice expressing humoral immunity.

Authors:  I A Ramshaw; P A Bretscher; C R Parish
Journal:  Eur J Immunol       Date:  1976-10       Impact factor: 5.532

3.  Depression of phagocytosis by solutes in concentrations found in the kidney and urine.

Authors:  I CHERNEW; A I BRAUDE
Journal:  J Clin Invest       Date:  1962-10       Impact factor: 14.808

4.  Primary immune response in cultures of spleen cells.

Authors:  J Marbrook
Journal:  Lancet       Date:  1967-12-16       Impact factor: 79.321

5.  A lymph node weight assay for the graft-versus-host activity of rat lymphoid cells.

Authors:  W L Ford; W Burr; M Simonsen
Journal:  Transplantation       Date:  1970-09       Impact factor: 4.939

6.  The splenic suppressor cell. II. Suppression of mixed lymphocyte reaction by thymus-dependent adherent cells.

Authors:  H Folch; B H Waksman
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

7.  The splenic suppressor cell. I. Activity of thymus-dependent adherent cells: changes with age and stress.

Authors:  H Folch; B H Waksman
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

8.  Immunological enhancement in the pathogenesis of pyelonephritis.

Authors:  T E Miller; S Burnham; J D North
Journal:  Clin Exp Immunol       Date:  1976-05       Impact factor: 4.330

9.  Plasma inhibitors of lymphocyte response to phytohaemagglutinin in children with recurrent infections.

Authors:  M G Fitzgerald; C S Hosking
Journal:  Immunology       Date:  1976-01       Impact factor: 7.397

10.  Local immune response in experimental pyelonephritis.

Authors:  J D Lehmann; J W Smith; T E Miller; J A Barnett; J P Sanford
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

View more
  9 in total

1.  Aggravation by morphine and D-aspartic acid of pyelonephritis induced by i.v. inoculation of Staphylococcus aureus in rats.

Authors:  H Koyuncuoğlu; M Güngör; O Anğ; D Inanç; M Anğ-Küçüker; H Sağduyu; V Uysal
Journal:  Infection       Date:  1988       Impact factor: 3.553

2.  Cellular basis of host defence in pyelonephritis. I. Chronic infection.

Authors:  T E Miller; G Findon; S Cawley
Journal:  Br J Exp Pathol       Date:  1986-02

3.  Cellular basis of host defence in pyelonephritis. II. Acute infection.

Authors:  T E Miller; G Findon; S Cawley; I Clarke
Journal:  Br J Exp Pathol       Date:  1986-04

4.  Host immune status in uraemia III. Humoral response to selected antigens in the rat.

Authors:  J Nelson; D J Ormrod; D Wilson; T E Miller
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

5.  B lymphocyte colony formation in renal infection.

Authors:  T Miller; S Rawstorn; E Stewart
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

Review 6.  Host parasite interaction in urinary tract infection.

Authors:  C Svanborg-Edén; P de Man; U Jodal; H Linder; H Lomberg
Journal:  Pediatr Nephrol       Date:  1987-10       Impact factor: 3.714

7.  Experimental Candida albicans, Staphylococcus aureus, and Streptococcus faecalis pyelonephritis in diabetic rats.

Authors:  L Raffel; P Pitsakis; S P Levison; M E Levison
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

8.  Impairment of cell-mediated immunity in Pseudomonas aeruginosa pyelonephritis: lack of suppressor cell activity in vivo.

Authors:  V Colizzi; M Campa; C Garzelli; L Toca; G Bevilacqua; G Falcone
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

9.  Pregnancy bacteriuria and Escherichia coli.

Authors:  I R McFadyen
Journal:  J R Soc Med       Date:  1980-04       Impact factor: 18.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.